Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00510510 · ClinicalTrials.gov registry record · Phase 2

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis.

Completed
Registry status
Phase 2
Development phase
281
Enrollment target
20
Study locations

NCT00510510 is a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Novartis. The registered enrollment target is 281 participants, below the 643-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00510510, a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Novartis.

COMPLETED
Registry status
Phase 2
Development phase
281 participants
Enrollment target
20
Study locations

Study Summary

This study assessed the safety/tolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day, compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD).

Conditions Studied

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • DRUG Placebo
  • DRUG NVA237 100 µg
  • DRUG NVA237 200 µg

Study Locations (20)

Other

  • Novartis investigative site - Rueil-Malmaison
  • Novartis investigative site - Nuremberg
  • Novartis investigative site - Arnhem
  • Novartis investigative site - Barcelona

Florida

  • Novartis investigative site - Miami
  • Novartis investigative site - Miami
  • Novartis investigative site - Tamarac

Arizona

  • Novartis investigative site - Glendale
  • Novartis investigative site - Phoenix

South Carolina

  • Novartis investigative site - Spartanburg
  • Novartis investigative site - Union

Texas

  • Novartis investigative site - Fort Worth
  • Novartis investigative site - Houston

Colorado

  • Novartis investigative site - Wheat Ridge

Delaware

  • Novartis investigative site - Newark

Illinois

  • Novartis investigative site - River Forest

Trial Details

FieldValue
Enrollment Target 281 participants
Start Date 2007-08
Est. Completion 2008-01
Phase Phase 2

Sponsor

Novartis

265 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00510510

The ClinicalTrials.gov registry entry for NCT00510510 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 643-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (56% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00510510 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00510510 about?

NCT00510510 is a clinical study titled "Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease". This study assessed the safety/tolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day, compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD).

What is the current status of trial NCT00510510?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 281 participants. The study started on 2007-08. Estimated completion is 2008-01.

What conditions does trial NCT00510510 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).

What interventions are being tested in trial NCT00510510?

The interventions under investigation include: Placebo (DRUG), NVA237 100 µg (DRUG), NVA237 200 µg (DRUG).

Who is sponsoring clinical trial NCT00510510?

This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00510510 being conducted?

This trial has 20 study locations across Arizona, Colorado, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Obstructive Pulmonary Disease (COPD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Obstructive Pulmonary Disease (COPD)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.